自體免疫疾病治療市場規模、佔有率和成長分析：按藥物類別、適應症、給藥途徑、分銷管道和地區分類－2026-2033年產業預測

2024 年全球自體免疫疾病治療市場價值為 1,305 億美元，預計到 2033 年將成長至 2,242.5 億美元，而 2025 年為 1,385.9 億美元，預測期（2026-2033 年）複合年成長率為 6.2%。

全球自體免疫疾病治療市場涵蓋作用於免疫系統的藥物，用於治療類風濕性關節炎、多發性硬化症和乾癬等疾病。自體免疫疾病的盛行率不斷上升，影響全球約5-8%的人口，這是醫療保健成本顯著成長的主要因素。在科學進步的推動下，該市場正從以傳統免疫抑制劑為主轉向生物製藥和生物相似藥。推動該市場發展的關鍵因素包括：有利的報銷政策提高了患者獲得昂貴生物製藥的機會，以及現有藥物適應症的擴展開闢了新的收入來源。此外，人工智慧驅動的自動化正在改變包括標靶發現、患者分層和臨床試驗在內的各個方面，簡化流程並提高效率，同時促進該領域的創新和成長。

全球自體免疫疾病治療市場的成長要素

全球自體免疫疾病盛行率的上升推動了對創新療法的需求，進而促使製藥公司加強研發力度，最終將新藥推向市場。此外，人們對自體免疫疾病的認知不斷提高，以及對有效療法的臨床需求日益成長，也進一步推動了這一成長。醫療專業人員正在採用更全面的篩檢方法，從而實現早期診斷，擴大了可從這些療法中獲益的患者群體。同時，患者權益倡導組織也在努力提高公眾對自體免疫疾病的認知，提升對前沿療法的接受度，並支持簡化監管流程，所有這些因素共同促進了該行業的強勁成長。

全球自體免疫疾病治療市場的限制因素

全球自體免疫疾病治療市場面臨許多限制因素，主要原因在於許多藥物高成本。這給患者和醫療系統都帶來了沉重的經濟負擔。這種經濟負擔限制了這些藥物的廣泛應用，增加了獲得保險報銷的難度，並最終阻礙了市場成長。保險公司通常會對處方藥清單施加嚴格限制，並要求提供詳細的用藥理由才能獲得保險報銷。這可能導致醫療服務提供者不願意開立昂貴且具有創新性的療法。因此，患者可能會停止治療或選擇療效較差的治療方案，導致對尖端產品的需求下降，開發平臺進展停滯不前，以及對臨床研究的長期投資減少。

全球自體免疫疾病治療市場趨勢

全球自體免疫疾病治療市場正經歷一場變革，而個人化生物製藥療法的興起正是推動這項變革的關鍵。這些療法專注於針對特定免疫路徑的治療，並根據每位患者的獨特特徵進行客製化，這得益於基因組學和生物標記研究的進步。這種個人化不僅提高了治療的療效和安全性，也促使醫療專業人員更快地將創新療法應用於臨床實踐。此外，支付方越來越接受基於價值的契約，這些契約以特定患者亞群中已證實的治療效果為條件，從而擴大了精準藥物的可及性和報銷範圍，進而加速了其在全球市場的滲透。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球自體免疫疾病治療市場規模：依藥物類別分類

• 腫瘤壞死因子抑制劑
• 白細胞介素抑制劑
• B細胞抑制劑
• T細胞抑制劑
• 免疫抑制劑
• 皮質類固醇
• 非類固醇消炎劑
• 其他

全球自體免疫疾病治療市場規模：依疾病適應症分類

• 類風濕性關節炎
• 銀屑病
• 多發性硬化症
• 發炎性腸道疾病
  • 克隆氏症
  • 潰瘍性大腸炎
• 全身性紅斑性狼瘡
• 1型糖尿病
• 其他

全球自體免疫疾病治療市場規模：依給藥途徑分類

• 口服
• 皮下注射
• 靜脈注射
• 其他

全球自體免疫疾病治療市場規模：按分銷管道分類

• 醫院藥房
• 零售藥房
• 網路藥房

全球自體免疫疾病治療市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• AbbVie Inc.
• Johnson & Johnson Services, Inc.
• Amgen Inc.
• Bristol Myers Squibb Company
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd
• Sanofi SA
• Novartis AG
• Eli Lilly and Company
• Ucb SA
• Merck & Co., Inc.
• Takeda Pharmaceutical Company Limited
• Bayer AG
• Eisai Co., Ltd.
• GlaxoSmithKline plc
• Astellas Pharma Inc.
• Biogen Inc.
• Incyte Corporation
• Horizon Therapeutics plc
• Teijin Pharma Limited

結論與建議

Global Autoimmune Drugs Market size was valued at USD 130.5 Billion in 2024 and is poised to grow from USD 138.59 Billion in 2025 to USD 224.25 Billion by 2033, growing at a CAGR of 6.2% during the forecast period (2026-2033).

The global market for autoimmune drugs encompasses pharmaceuticals that influence the immune system to address conditions like rheumatoid arthritis, multiple sclerosis, and psoriasis. The increasing prevalence of autoimmune disorders, impacting approximately 5-8% of the global population, significantly contributes to healthcare costs. The market has evolved from a focus on traditional immunosuppressants to a greater emphasis on biologics and biosimilars, fueled by scientific advancements. Key factors driving this market include favorable reimbursement policies that enhance patient access to high-cost biologics, as well as expanded indications for existing medications, which open new revenue avenues. Additionally, AI-driven automation is transforming various aspects, such as target discovery, patient stratification, and clinical trials, streamlining processes and improving efficiency while fostering innovation and growth within the sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Autoimmune Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Autoimmune Drugs Market Segments Analysis

Global autoimmune drugs market is segmented by drug class, disease indication, route of administration, distribution channel and region. Based on drug class, the market is segmented into Tumor Necrosis Factor Inhibitors, Interleukin Inhibitors, B-Cell Inhibitors, T-Cell Inhibitors, Immunosuppressants, Corticosteroids, Non-Steroidal Anti-Inflammatory Drugs and Others. Based on disease indication, the market is segmented into Rheumatoid Arthritis, Psoriasis, Multiple Sclerosis, Inflammatory Bowel Disease, Systemic Lupus Erythematosus, Type 1 Diabetes and Others. Based on route of administration, the market is segmented into Oral, Subcutaneous Injection, Intravenous Infusion and Others. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Autoimmune Drugs Market

The rising prevalence of autoimmune diseases worldwide is driving the demand for innovative therapeutic solutions, which encourages pharmaceutical companies to enhance their research and development efforts, resulting in the introduction of new medications to the market. This growth is further propelled by increased awareness of autoimmune disorders and the clinical necessity for effective treatments. Healthcare professionals are implementing more comprehensive screening methods, facilitating earlier diagnostics and expanding the pool of patients who can benefit from these therapies. Additionally, advocacy organizations are improving public knowledge, fostering greater acceptance of cutting-edge treatments, and supporting streamlined regulatory processes, collectively contributing to a robust growth cycle within the industry.

Restraints in the Global Autoimmune Drugs Market

The Global Autoimmune Drugs market faces several restraints primarily due to the high costs associated with many medications, which places a significant financial strain on both patients and healthcare systems. This economic burden limits the widespread use of these drugs and presents challenges in securing reimbursement, ultimately hindering market growth. Insurers frequently implement stringent formulary restrictions, requiring extensive justification for coverage approval, which can dissuade healthcare providers from prescribing more expensive, innovative treatments. As a result, patients may withdraw from therapies or choose less effective options, diminishing demand for cutting-edge products and stalling advancements in the development pipeline and long-term clinical research investments.

Market Trends of the Global Autoimmune Drugs Market

The Global Autoimmune Drugs market is experiencing a transformative trend driven by the emergence of personalized biologic therapies. These therapies focus on targeting specific immune pathways tailored to the unique profiles of individual patients, made possible by advancements in genomics and biomarker research. This tailoring not only enhances treatment efficacy and safety but also encourages healthcare providers to incorporate innovative therapies sooner in clinical practice. Additionally, the increasing acceptance of value-based contracts among payers, contingent upon demonstrated outcomes in specific patient subpopulations, is facilitating broader access and reimbursement for these precision medicines, thus propelling their global market penetration.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Autoimmune Drugs Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Tumor Necrosis Factor Inhibitors
• Interleukin Inhibitors
• B-Cell Inhibitors
• T-Cell Inhibitors
• Immunosuppressants
• Corticosteroids
• Non-Steroidal Anti-Inflammatory Drugs
• Others

Global Autoimmune Drugs Market Size by Disease Indication & CAGR (2026-2033)

• Market Overview
• Rheumatoid Arthritis
• Psoriasis
• Multiple Sclerosis
• Inflammatory Bowel Disease
  • Crohns Disease
  • Ulcerative Colitis
• Systemic Lupus Erythematosus
• Type 1 Diabetes
• Others

Global Autoimmune Drugs Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Subcutaneous Injection
• Intravenous Infusion
• Others

Global Autoimmune Drugs Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Autoimmune Drugs Market Size & CAGR (2026-2033)

• North America (Drug Class, Disease Indication, Route of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Disease Indication, Route of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Disease Indication, Route of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Disease Indication, Route of Administration, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Disease Indication, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ucb S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Horizon Therapeutics plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teijin Pharma Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations